The FDA has approved Anascorp (Centruroides immune F(ab) 2 injection; Rare Disease Therapeutics), an antivenom, for the treatment of scorpion stings by Centruroides scorpions. This approval was based on results from a randomized, double-blind, placebo-controlled trial of 15 children with neurological signs of scorpion stings. These signs resolved within 4 hours of treatment in the eight subjects who received Anascorp, but in only one of the seven participants who received placebo. In total, safety and efficacy data was collected from 1,534 patients in both open-label and blinded studies.
For more information call (615) 399-0700 or visit www.raretx.com.